MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days + Comparator: amikacin / Duration of Treatment: 3 Days + Comparator: tazocin / Duration of Treatment: 3 Days + Comparator: vancomycin / Duration of Treatment: 3 Days
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Infection
Conditions
Infection, Pneumonia
Trial Timeline
Nov 1, 2006 → Jan 1, 2007
NCT ID
NCT00445094About MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days + Comparator: amikacin / Duration of Treatment: 3 Days + Comparator: tazocin / Duration of Treatment: 3 Days + Comparator: vancomycin / Duration of Treatment: 3 Days
MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days + Comparator: amikacin / Duration of Treatment: 3 Days + Comparator: tazocin / Duration of Treatment: 3 Days + Comparator: vancomycin / Duration of Treatment: 3 Days is a approved stage product being developed by Merck for Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00445094. Target conditions include Infection, Pneumonia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00445094 | Approved | Completed |
Competing Products
20 competing products in Infection